Brown tumor of the jaw after pregnancy and lactation in a MEN1 patient by Casteràs, Anna et al.
AUTHOR COPY ONLY
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivs 3.0 
Unported License.
© 2016 The authors http://www.edmcasereports.com
 Published by Bioscientifica Ltd
ID: 16-0111; November 2016
DOI: 10.1530/EDM-16-0111
Brown tumor in MEN1A Casteràs and others
Brown tumor of the jaw after pregnancy and 
lactation in a MEN1 patient
Anna Casteràs1, Lídia Darder2, Carles Zafon1, Juan Antonio Hueto2, 
Margarita Alberola4, Enric Caubet3 and Jordi Mesa1
1Department of Endocrinology, 2Department of Maxilofacial Surgery, 3Department of Pathology and 
4Department of Endocrine Surgery, University Hospital Vall d’Hebron, Barcelona, Spain
Summary
Skeletal manifestations of primary hyperparathyroidism (pHPT) include brown tumors (BT), which are osteoclastic 
focal lesions often localized in the jaws. Brown tumors are a rare manifestation of pHTP in Europe and USA; however, 
they are frequent in developing countries, probably related to vitamin D deficiency and longer duration and severity 
of disease. In the majority of cases, the removal of the parathyroid adenoma is enough for the bone to remineralize, 
but other cases require surgery. Hyperparathyroidism in MEN1 develops early, and is multiglandular and the timing of 
surgery remains questionable. To our knowledge, there are no reports of BT in MEN 1 patients. We present a 29-year-old 
woman with MEN 1 who developed a brown tumor of the jaw 24 months after getting pregnant, while breastfeeding. 
Serum corrected calcium remained under 2.7 during gestation, and at that point reached a maximum of 2.82 mmol/L. 
Concomitant PTH was 196 pg/mL, vitamin D 13.7 ng/mL and alkaline phosphatase 150 IU/L. Bone mineral density showed 
osteopenia on spine and femoral neck (both T-scores = −1.6). Total parathyroidectomy was performed within two weeks, 
with a failed glandular graft autotransplantation, leading to permanent hypoparathyroidism. Two months after removal 
of parathyroid glands, the jaw tumor did not shrink; thus, finally it was successfully excised. We hypothesize that higher 
vitamin D and mineral requirements during maternity may have triggered an accelerated bone resorption followed 
by appearance of the jaw BT. We suggest to treat pHPT before planning a pregnancy in MEN1 women or otherwise 
supplement with vitamin D, although this approach may precipitate severe hypercalcemia.
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Learning points:
•	 Brown tumors of the jaw can develop in MEN 1 patients with primary hyperparathyroidism at a young age  
(less than 30 years).
•	 Pregnancy and lactation might trigger brown tumors by increasing mineral and vitamin D requirements.
•	 Early parathyroidectomy is advisable in MEN 1 patients with primary hyperparathyroidism, at least before planning 
a pregnancy.
•	 Standard bone mineral density does not correlate with the risk of appearance of a brown tumor.
•	 Removal of parathyroid glands does not always lead to the shrinkage of the brown tumor, and surgical excision 
may be necessary.
Background
In recent years, the majority of patients with primary 
hyperparathyroidism (pHPT) in developed countries are 
asymptomatic, detected on routine testing and less than 
5% display classic skeletal lesions named osteitis fibrosa 
cystica (OFC) (1). Brown tumors (BT), a localized form 
of OFC, are central giant cell lesions that are believed 
to occur in patients with severe or longstanding 
hyperparathyroidism. Very high PTH levels are frequently 
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found/associated in/with brown tumors, which have 
also been reported in secondary HPT, parathyroid 
carcinoma as well as paraneoplastic syndrome (PTHrP) 
(2). Although they are a rare finding in Europe and USA, 
brown tumors are common in developing countries 
affecting more than half of the patients (3). These 
figures are attributed to malnourishment and vitamin D 
deficiency, added to a delayed diagnosis. In that sense, 
pregnancy and breastfeeding have not been linked to 
BT development and only a couple of cases are found in 
literature. A hallmark of multiple endocrine neoplasia 
type 1 (MEN 1) is the early development of pHPT, but no 
cases of BT have been reported in adolescents and young 
adults, compatible with regular screening and early 
parathyroidectomy. BT generally shrinks or resolves 
after parathyroidectomy, but some cases may require 
surgery due to rapid progression or location affecting 
vital structures.
Case presentation
A female patient carrier of a MEN 1 mutation 
(p.Val184Glu in exon 3 of MEN1 gene) was first screened 
for associated neoplasms at the age of 28 years. Primary 
hyperparathyroidism was the only comorbidity found 
at that time. MRI images and hormonal studies failed 
to demonstrate gastroenteropancreatic neuroendocrine 
tumors, as well as pituitary adenoma.
Serum total calcium was 2.74 mmol/L initially 
(normal values 2.2–2.54), with normal serum phosphate 
(0.87 mmol/L, n.v. 0.8–1.45) and mildly elevated PTH 
(146 pg/mL; n.v. 14.5–87.1). Vitamin D status was 
suboptimal (15 ng/mL; n.v. 31–80), but no specific 
supplementation was recommended apart from diet and 
sun exposure. Bone mineral density (BMD) scan showed 
osteopenia in spine (T −1.05), but normal density in 
femoral neck. She did not suffer from complications such 
as nephrolithiasis, bone pain or deformities.
Localization studies found a cervical nodule 
compatible with parathyroid adenoma on the left side on 
ultrasound, which correlated with a high MIBI uptake on 
scintigraphy. At that time, surgery was advised, but she 
moved abroad and was postponed.
A year thereafter (29 years) she got pregnant and gave 
birth to a female healthy baby without obstetric problems. 
During pregnancy, calcium was maintained below 
2.7 mmol/L. Abundant hydration was recommended, but 
no vitamin D or calcium supplementation was provided 
apart from a healthy diet.
Suddenly, 15  months after delivery, the patient 
noticed a palpable and visible swelling in the right-
sided mandible, which doubled volume in 2  months. 
She was still breastfeeding but was advised against 
at that moment. At that point, serum calcium level 
had reached a maximum of 2.82 mmol/L, phosphate 
remained normal, concomitant PTH was 196 pg/mL, 
vitamin D 13.7 ng/mL and alkaline phosphatase 
Figure 1 
Computed tomography: well-demarcated monolocular osteolytic lesion 
on the right side of the mandibular body. Cortical bone is expanded and 
thinned.
Figure 2 
Surgical view during the removal of the mandibular tumor.
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150 IU/L (n.v. 30–120) (Table 1) . Bone mineral density 
showed increasing osteopenia on spine and femoral 
neck (both T-scores = −1.6).
Physical examination by maxillofacial surgeon 
detected cortical bulging and fluctuation in vestibular 
inner side. Computed tomography showed a mandibular 
cyst, compatible with a brown tumor according to the 
medical information.
Physical exam at this time gave a body weight of 
80 kg, height 165 cm, blood pressure 107/67, with no 
signs of pituitary hyper/hypofunction.
Investigation
Computed tomography (Fig.  1): well-demarcated 
monolocular osteolytic lesion on the right side of the 
mandibular body. Cortical bone is expanded and thinned.
Bone scintigraphy: retention only on mandible.
Tumor biopsy: giant cell tumor.
Treatment
Parathyroidectomy was performed two weeks thereafter, 
four glands were removed and half of one was transplanted 
into the left sternocleidomastoid muscle. Pathological 
exam revealed a parathyroid adenoma sized 2 × 1 × 0.5 cm 
in the left superior gland, and hyperplasia on another 
gland. Prophylactic thymectomy was done in the same act. 
Postoperatively mild hypocalcemia developed, probably 
related to hungry bone syndrome. Besides, the parathyroid 
graft failed, and permanent hypoparathyroidism is under 
control with calcitriol 1 μg and calcium carbonate 2400 mg 
daily. The mandibular cyst did not shrink 2 months after 
parathyroidectomy, and even displayed some growth, 
putting teeth in danger. Enucleation was then carried out 
(Fig. 2) with good aesthetic results.
Outcome and follow-up
Pathology study showed a 4 cm giant cell granuloma 
(Fig. 3). The mandibular tumor has not reappeared after 
20-month follow-up. As a collateral adverse event, she 
displays anesthesia on the mentonian area.
Discussion
Skeletal involvement in classic pHPT is characterized by 
a strikingly high rate of osteoclastic bone resorption. It 
is accompanied by a cellular repair process that results in 
the accumulation of fibrous stroma and connective tissue 
cells along with multinucleated giant cells. Brown tumors 
are osteolytic focal giant cell lesions localized in areas of 
intense bone resorption, preferentially facial skeleton (e.g. 
mandible, maxilla) but also clavicle, ribs and pelvic bones.
BTs are not true neoplasms, but they can be locally 
aggressive and mimic malignancies. Histological features 
alone cannot establish a certain diagnosis; thus, it should 
be confirmed by the endocrine status of the patient. Among 
differential diagnosis of giant cell lesions, we have to consider 
Figure 3 
Hematoxylin-eosin staining (400× magnification) of the jaw mass. 
Proliferation of mesenchymal cells with oval nuclei and eosinophilic 
cytoplasm. Scattered throughout the stroma are numerous osteoclast-like 
multinucleated giant cells containing varying numbers of vesicular nuclei.
Table 1 Phosphor-calcium metabolism parameters.
Parameters
Reference 
values
At diagnosis 
(28 y)
Pregnancy Postpartum; Lactation
2 months after 
parathyroidectomy
1st trimester 
(29 y) 3rd trimester 7 months 15 months*
Calcium (mmol/L) 2.2–2.54 2.74 2.54 2.57 2.67 2.82 2.22
Phosphor (mmol/L) 0.8–1.45 0.87 1.06 0.87 0.8 1.19
PTH (pg/mL) 14.5–87.1 146 106 123 196 14
Vitamin D (ng/mL) 31–80 15.1 16.3 14 15.2 20
AKP (IU/L) 30–120 119 150 104
AKP, alkaline phosphatase; *Brown tumor appearance
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reparative giant cell granuloma, cherubism, aneurysmal 
bone cyst or true giant cell tumors. When localized in jaws, 
BT can also simulate ameloblastoma or odontogenic cysts. 
Ossifying fibromas of the mandible or maxilla, also known 
as cementifying fibromas occur in 30–40% of individuals 
with hyperparathyroidism-jaw tumor syndrome, included 
in CDC73-related disorders, but these tumors show different 
radiologic and histologic traits. On imaging, brown tumors 
appear as lytic lesions with regular borders and thinned 
cortical bone, not accompanied by periosteal reaction 
or inflammatory signs. Concomitant signs like salt-and-
pepper bone changes, subperiosteal bone resorption and 
disappearance of the lamina dura around the roots of the 
teeth may help with the differential diagnosis.
The incidence of brown tumors varies considerably 
among regions. In developing countries (e.g. India), OFC/
BTs are quite common, seen in 50–90% of patients. Primary 
HPT presents at younger ages than in Western countries, 
with higher levels of calcium and PTH, and larger adenomas, 
compatible with vitamin D depletion and skeletal PTH 
resistance. In Western countries, pHPT is uncommon in 
adolescents and young adults (3% of parathyroid surgeries) 
(5), BTs account for around 1.5% of all cases, and are rarely 
the first manifestations of pHPT.
BTs are in general more probable in people aged 
more than 50 years, as a manifestation of longstanding 
hyperparathyroidism, but there are several reports in 
young adults, presumably depending on the existence of 
vitamin D deficiency or other pathogenetic factors (3).
Proposed predictors of OFC or brown tumors are high 
levels of PTH and large parathyroid adenoma. BTs usually 
go with high alkaline phosphatase (more than 1000 IU/L), 
reflecting high bone turnover (4). Bone densitometry 
seems not predictive for BT, but this is not well studied.
BTs are in general three times more common in women 
than in men. The female predominance could be related to 
different phosphocalcic metabolism, with less sun exposure, 
and more calcium and vitamin D requirements during 
maternity. Although this has not been addressed properly, 
there are 2 reports of BT occurring in pregnant women 
(5, 6), but vitamin D status is not reported. Indian series 
do not inform of a temporal relationship with eventual 
pregnancies or breastfeeding among affected women.
During lactation, maternal calcium and bone 
metabolism must adapt to an extra demand for calcium 
(300–400 mg/days). The major source calcium in this 
setting is bone, and to a lower extent, increased dietary 
calcium intake and renal retention (7). It is known 
that maternal bone mass declines during lactation, 
about 10% over the first 6  months (predominantly 
trabecular bone), whereas calcium levels rise slightly 
and PTH decreases. Lactating breast secretes PTHrP into 
the systemic circulation and into milk and is the only 
instance in which circulates, apart from malignancies. 
PTHrP mobilizes skeletal calcium stores to be delivered 
to the breast for milk. Concomitant estrogen deficiency 
secondary to hypogonadotrophic hypogonadism may 
increase bone turnover and bone loss. On the other 
hand, polymorphisms in vitamin D receptor (VDR) gene 
could contribute to differences in the skeletal response to 
lactation (8). These mechanisms, added to an underlying 
primary PTH in our patient, would have worsened bone 
lytic lesions, although these are speculative explanations.
In regard to MEN1, to our knowledge, there are no 
reports of brown tumors. In a wide French series (9), pHPT 
was present in 96% of patients, and already in 75% of 
those younger than 21 years (10). Mean age of diagnosis 
of pHPT was 16 ± 4 years and was very rare before 6 years. 
PHPT was the first manifestation of the disease in 56% 
of them, the majority by biological screening, being 
only 17% symptomatic (urolithiasis 86%, fatigue 33%, 
bone pain 1%). No gender-related differences in MEN1 
hyperparathyroidism occurrence were detected.
Opinions are divided on the course and management 
of the bony lesions once parathyroidectomy has been 
carried out. Reséndiz-Colosia et  al. (1) reported that of 
22 patients with BT (68.2% in the mandible, 31.8% 
in maxilla) all presented a spontaneous progressive 
regression after parathyroidectomy; indeed, in 18 cases it 
was resolved after 10  months. However, the tumor can 
display different response patterns (3), and if it is very 
destructive, disfiguring or causes functional problems, 
surgical excision may be indicated as in our case.
On the other hand, OFC may regress at least in renal 
secondary hyperparathyroidism after oral therapy with 
vitamin D and subsequent reduction of PTH. Vitamin D 
receptor genotype may also regulate the response to the 
vitamin D supplementation.
Here arises the question whether pHTP should 
be replaced with vitamin D as it may not worsen 
hypercalcemia and can prevent skeletal disturbances, as 
well as ameliorate hungry bone syndrome after resection. 
Current guidelines recommend the measurement of 
serum 25-hydroxy-cholecalciferol and supplement if 
levels are less than 20 ng/mL. According to the present 
case, we fully agree, especially in childbearing age, aiming 
to avoid OFC. However, it seems safer to surgically solve 
pHPT before planning maternity.
In our case, PTH, calcemia or alkaline phosphatase 
was not too high, and standard bone density was not very 
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low; therefore, we attribute the development of BT to an 
acute bone mineral and vitamin depletion in gestation 
and breastfeeding.
Patient’s perspective
The patient suggests that an earlier mandibular tumor resection would 
have been more practical. 
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